临床试验/IRCT20210519051345N15

IRCT20210519051345N15尚未招募未知

Fasted-state in vivo bioequivalence study of Celecoxib 100 mg tablet manufactured by Farnoush Daru Teb Co. compared with innovator product

Tabriz University of Medical Sciences0 个研究点目标入组 24 人开始时间: 待定最近更新: 2022年8月29日

试验速览

阶段: 未知
状态: 尚未招募
发起方: Tabriz University of Medical Sciences
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 years 至 59 years（—）
性别: All

入选标准

•General Health (in terms of Liver, Heart and Kidney)

排除标准

•History of cardiovascular disease, liver and kidney disease,
•Alcohol and drug addiction,
•History of drug allergy

研究者

发起方

Tabriz University of Medical Sciences

相似试验

Bioequivalence study of Gliclazide 60 mg tablet

IRCT20210519051345N63Tabriz University of Medical Sciences24

Bioequivalence study of Gliclazide 60 mg tablet

IRCT20210519051345N43Tabriz University of Medical Sciences24

Investigating the in vivo bioequivalence of Escitalopram 20 mg tabletIn the present study, the products will be administered to healthy volunteers.

IRCT20210519051345N55Tabriz University of Medical Sciences24

Bioequivalence study of Desloratadine 5 mg tablet

IRCT20210519051345N49Tabriz University of Medical Sciences24

Bioequivalence study of Calcium Dobesilate 500 mg capsule

IRCT20210519051345N38Tabriz University of Medical Sciences24